Search

A leader in developing better treatments for a range of blood cancers, Dr. Omar Abdel-Wahab is only the second person from MSK to receive the Paul Marks Prize for Cancer Research. 

… Monday, December 1, 2025 For more than two decades, physician-scientist Omar Abdel-Wahab, MD , has been known around Memorial Sloan Kettering Cancer Center (MSK) for his insight, knowledge, and creativity as a cancer researcher.   Now he will also be known as a Paul Marks Prize winner , the first recipient

Andy Minn, MD, PhD, will return to Memorial Sloan Kettering Cancer Center (MSK) as the inaugural Chair of MSK’s new Immuno-Oncology Program in August.

… Thursday, May 15, 2025 Andy Minn, MD, PhD, will return to Memorial Sloan Kettering Cancer Center (MSK) as the inaugural Chair of MSK’s new Immuno-Oncology Program in August. This is a full-circle moment for Dr. Minn, a renowned physician-scientist, who completed his postdoctoral training with  Joan Massagué

Memorial Sloan Kettering Cancer Center has announced that Oren Cahlon, MD, a renowned radiation oncologist and expert in proton therapy, will assume the position of Associate Deputy Physician-in-Chief for the Memorial Sloan Kettering Regional Care Network. With this appointment, which is effective immediately, Dr. Cahlon will help oversee the network’s outpatient clinical programs, which span seven locations across New York and New Jersey.

… Friday, November 23, 2018 Memorial Sloan Kettering Cancer Center has announced that Oren Cahlon, MD , a renowned radiation oncologist and expert in proton therapy, will assume the position of Associate Deputy Physician-in-Chief for the Memorial Sloan Kettering Regional Care Network. With this appointment

Memorial Sloan Kettering Cancer Center (MSK) announced today that the US Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation to cobimetinib in treatment of patients with histiocytic neoplasms (HN) (Erdheim-Chester Disease, Rosai-Dorfman, Langerhans Histiocytosis), who do not harbor the BRAF V600 mutation. Cobimetinib is an oral inhibitor of MEK1 and MEK2 currently approved to treat melanoma. This designation was granted based on data submitted by MSK, in collaboration with Genentech, a member of the Roche Group, from a phase II trial of single-agent cobimetinib for adults with histiocytic disorders (published in Nature in March 2019 by Eli Diamond, MD; Omar Abdel-Wahab, MD; and David Hyman, MD).

… Wednesday, October 2, 2019 Bottom Line: Memorial Sloan Kettering Cancer Center (MSK) announced today that the US Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation to cobimetinib in treatment of patients with histiocytic neoplasms (HN) (Erdheim-Chester Disease, Rosai-Dorfman

Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.

… Thursday, October 8, 2015 Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which

Early CD4+ T cell reconstitution predicted non-relapsing mortality and overall survival in pediatric patients who received an allogeneic hematopoietic stem cell transplant (HCT) and developed acute graft-versus-host disease.

… Thursday, January 14, 2021 Early CD4+ T cell reconstitution predicted non-relapsing mortality and overall survival (OS) in pediatric patients who received an allogeneic hematopoietic stem cell transplant (HCT) and developed acute graft-versus-host disease (GVHD), according to our research published recently

MSK experts believe that giving the targeted drug asciminib to patients with chronic myeloid leukemia at the beginning of their treatment offers them a better chance of being cured.

… Friday, January 17, 2025 When Aaron von Freter learned he had  chronic myeloid leukemia (CML) , he “felt like the room was spinning,” he remembers. “I thought I’d been served a death sentence.” Aaron was 45 years old and had no symptoms. His CML diagnosis came after standard bloodwork revealed an extremely

Third-year students Oakley Olsen and Alison Spencer have been named Grayer Fellows. Fellows are chosen based on excellence demonstrated by their thesis proposal examinations.

… Monday, October 10, 2011 Third-year students Oakley Olsen and Alison Spencer have been named Grayer Fellows. These fellowships were established by Mr. and Mrs. Jonathan Grayer. Mr. Grayer is a member of the Gerstner Sloan Kettering Board of Trustees and the former chairman and CEO of Kaplan, Inc., which

Former leader of Memorial Sloan Kettering Paul Marks gives a compelling view of cancer research and treatment over the past 40 years in On the Cancer Frontier: One Man, One Disease, and a Medical Revolution.

… Wednesday, April 16, 2014 Summary Former leader of Memorial Sloan Kettering Paul Marks gives a compelling view of cancer research and treatment over the past 40 years in On the Cancer Frontier: One Man, One Disease, and a Medical Revolution . Paul Marks — who served as President and Chief Executive Officer

New MSK research develops a new tool for studying mitochondrial DNA deletions; uncovers mechanisms of histiocytosis-associated neurodegeneration; and investigates how mutant stem cells co-opt regeneration to make tumors grow.

… Wednesday, March 26, 2025 New research from Memorial Sloan Kettering Cancer Center (MSK) develops a new tool for studying mitochondrial DNA deletions; uncovers mechanisms of histiocytosis-associated neurodegeneration; and investigates how mutant stem cells co-opt regeneration to make tumors grow. A new